MIB Agents accepting applications for annual OutSmarting Osteosarcoma research grants

OMB draft rule politicizing research should be rescinded, House Dems urge in a letter to Bhattacharya

Democratic leaders of the House Committee on Energy and Commerce are urging NIH Director Jay Bhattacharya to voice objections to a proposed rule from the Office of Management and Budget that would give the administration unprecedented political control over government-funded science.

June 26, 2026

Vol.52 No.25

By Jacquelyn Cobb

Funding Opportunities

The Foundation for AIDS Research opens RFP to fund non-HIV cancer research

Historically, the research initiatives of the Foundation for AIDS Research (amfAR) have focused on finding a cure for HIV. Four decades of HIV research have reshaped our understanding of the immune system, and insights from HIV have been leveraged in adjacent fields, including cancer immunology. Innovation can be bi-directional and reciprocal. Seminal findings in cancer immunology have also furthered understanding of HIV biology.

June 26, 2026

Vol.52 No.25

Drugs & Targets

FDA approves Tecelra for pediatric synovial sarcoma

FDA granted full approval of Tecelra (afamitresgene autoleucel) and expanded its indication to include pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or cleared companion diagnostic devices.

June 26, 2026

Vol.52 No.25

Capitol Hill

House bill gives NCI $7.4 billion in FY 2027—$110 million above current budget

On June 9, the House Appropriations Committee passed its version of the fiscal year 2027 spending bill for Labor, Health and Human Services, and Education.

June 12, 2026

Vol.52 No.23

By Paul Goldberg

Political appointees to be inserted into all stages of making research funding awards if OMB rule becomes final

The White House Office of Management and Budget has released a 412-page proposal that inserts political appointees into all stages of reviewing and awarding of federal research grants.

June 05, 2026

Vol.52 No.22

By Paul Goldberg and Claire Marie Porter

Clinical Roundup

OST-HER2 achieves 2.5-year OS in fully resected pulmonary metastatic osteosarcoma, phase IIb trial finds

OST-HER2 (OST31-164) achieved statistically significant benefit for treated patients in overall survival at the 2.5-year timepoint in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma (75% vs. 47%, p = 0.003).

June 05, 2026

Vol.52 No.22

MIB Agents accepting applications for annual OutSmarting Osteosarcoma research grants

YOU MAY BE INTERESTED IN

OMB draft rule politicizing research should be rescinded, House Dems urge in a letter to Bhattacharya

The Foundation for AIDS Research opens RFP to fund non-HIV cancer research

FDA approves Tecelra for pediatric synovial sarcoma

House bill gives NCI $7.4 billion in FY 2027—$110 million above current budget

Political appointees to be inserted into all stages of making research funding awards if OMB rule becomes final

OST-HER2 achieves 2.5-year OS in fully resected pulmonary metastatic osteosarcoma, phase IIb trial finds

Renew today!

Subscriber content

Never miss an issue!

Login